Log In
BCIQ
Print this Print this
 

ketoconazole HRA

  Manage Alerts
Collapse Summary General Information
Company HRA Pharma S.A.
DescriptionOral imidazole derivative that inhibits cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17; CYP17A), an enzyme involved in cortisol synthesis
Molecular Target Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of ActionCytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationCushing's disease
Indication DetailsTreat Cushing's syndrome; Treat endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years
Regulatory Designation EU - Orphan Drug (Treat endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years);
Switzerland - Orphan Drug (Treat Cushing's syndrome)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today